Description: LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
Home Page: lunglifeai.com
2545 West Hillcrest Drive
Thousand Oaks,
CA
91320
United States
Phone:
805 409 9868
Officers
| Name | Title |
|---|---|
| Dr. Paul Pagano Ph.D. | CEO, Chief Scientific Officer & Executive Director |
| Mr. David M. Anderson | CFO, Company Secretary & Executive Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4295 |
| Price-to-Sales TTM: | 124.534 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |